Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
What target volume and dose would you boost for inflammatory breast cancer with prepectoral saline implant?
Answer from: Radiation Oncologist at Community Practice
There is no defined boost volume and if has a poor response to chemo, would take tangential chest wall field to mid 50s dose.
Sign in or Register to read more
10571
Related Questions
Would you feel comfortable doing high tangents with ultra-hypofractionation?
Given the final publication of NSABP B-51, for which patients meeting trial eligibility would you still recommend regional nodal irradiation?
Would you recommend PMRT to a clinically node positive (biopsy proven axillary node and indeterminate single IMN node) BRCA positive patient with multiple medical co-morbidities including scleroderma and ILD who is treated with neoadjuvant chemotherapy (NAC) and mastectomy who converts to ypT0/ypN0?
When treating chestwall + RNI with VMAT, how much do you crop the PTV into lung as is done with the PTVeval in 3D contouring guides?
Under what circumstances would you pursue completion ALND in a patient with multiple positive sentinel nodes after breast-conserving surgery?
Does radiation therapy (ex. to the breast) in patients with CDK4 mutations increase the risk of developing melanoma?
Is there any increased risk with adjuvant breast radiation for a patient with muscular dystrophy?
What is your approach to women with breast cancer who opts for a staged approach with up-front lumpectomy and SLN biopsy (pN-) when there are indications for adjuvant radiation therapy but she plans for a later mastectomy (=>6 months)?
Does a post-surgical hematoma in the breast affect your recommendations for partial breast RT?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?